{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:33:47Z","timestamp":1792478027367,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015083","name":"Peking University People's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RDX2018-01"],"award-info":[{"award-number":["RDX2018-01"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.heliyon.2024.e34094","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T03:54:58Z","timestamp":1720065298000},"page":"e34094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["PRAME promotes proliferation of multiple myeloma cells through CTMP\/Akt\/p21\/CCND3 axis by ubiquitinating CTMP and p21"],"prefix":"10.1016","volume":"10","author":[{"given":"Kai","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Yan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1548-0946","authenticated-orcid":false,"given":"Ya-Zhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e34094_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e34094_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif."},{"key":"10.1016\/j.heliyon.2024.e34094_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/genes13030545","article-title":"Preferentially expressed antigen in melanoma (PRAME) and human malignant melanoma: a retrospective study","volume":"13","author":"Cazzato","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.heliyon.2024.e34094_bib4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-007-9643-3","article-title":"Prevalence and prognostic and predictive relevance of PRAME in breast cancer","volume":"109","author":"Doolan","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.heliyon.2024.e34094_bib5","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.heliyon.2024.e34094_bib6","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.ejca.2006.06.026","article-title":"Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors","volume":"42","author":"Partheen","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e34094_bib7","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.heliyon.2024.e34094_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1054\/drup.1999.0095","article-title":"Proteasome inhibitors as potential novel anticancer agents","volume":"2","author":"Dou","year":"1999","journal-title":"Drug Resist. Updates : reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.heliyon.2024.e34094_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.heliyon.2024.e34094_bib10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.heliyon.2024.e34094_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2024.e34094_bib12","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3760\/cma.j.issn.0366-6999.20132356","article-title":"Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma","volume":"127","author":"Qin","year":"2014","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.heliyon.2024.e34094_bib13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/1521-4141(200003)30:3<803::AID-IMMU803>3.0.CO;2-P","article-title":"The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells","volume":"30","author":"Pellat-Deceunynck","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34094_bib14","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1089\/dna.2017.3951","article-title":"PRAME gene copy number variation is related to its expression in multiple myeloma","volume":"36","author":"Yang","year":"2017","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.heliyon.2024.e34094_bib15","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1038\/emboj.2011.262","article-title":"The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters","volume":"30","author":"Costessi","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.heliyon.2024.e34094_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058052","article-title":"PRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPs","volume":"8","author":"Wadelin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e34094_bib17","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.2147\/OTT.S240979","article-title":"Both methylation and copy number variation participated in the varied expression of PRAME in multiple myeloma","volume":"13","author":"Yang","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.heliyon.2024.e34094_bib18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjh.15878","article-title":"S100A16 suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia","volume":"185","author":"Zhang","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e34094_bib19","doi-asserted-by":"crossref","first-page":"6316","DOI":"10.1038\/s41467-020-20107-1","article-title":"TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e34094_bib20","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e34094_bib21","doi-asserted-by":"crossref","first-page":"10639","DOI":"10.1158\/0008-5472.CAN-06-2522","article-title":"A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer","volume":"66","author":"Epping","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e34094_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34094_bib23","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/j.ejca.2006.06.018","article-title":"Childhood acute myelogenous leukaemia: association between PRAME, apoptosis- and MDR-related gene expression","volume":"42","author":"Goellner","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e34094_bib24","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/s41418-020-00724-5","article-title":"Tumor-associated antigen Prame targets tumor suppressor p14\/ARF for degradation as the receptor protein of CRL2(Prame) complex","volume":"28","author":"Zhang","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.heliyon.2024.e34094_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13046-019-1058-6","article-title":"FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21","volume":"38","author":"Zhang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res. : CRN"},{"key":"10.1016\/j.heliyon.2024.e34094_bib26","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.7150\/ijbs.72014","article-title":"HERC3 directly targets RPL23A for ubiquitination degradation and further regulates Colorectal Cancer proliferation and the cell cycle","volume":"18","author":"Zhang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.heliyon.2024.e34094_bib27","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s11064-016-1932-y","article-title":"Elevated expression of carboxy-terminal modulator protein (CTMP) aggravates brain ischemic injury in diabetic db\/db mice","volume":"41","author":"Chen","year":"2016","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.heliyon.2024.e34094_bib28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.metabol.2013.10.012","article-title":"New players in high fat diet-induced obesity: LETM1 and CTMP","volume":"63","author":"Park","year":"2014","journal-title":"Metab., Clin. Exp."},{"key":"10.1016\/j.heliyon.2024.e34094_bib29","doi-asserted-by":"crossref","first-page":"10740","DOI":"10.1073\/pnas.0904412106","article-title":"Signaling mechanisms involved in altered function of macrophages from diet-induced obese mice affect immune responses","volume":"106","author":"Zhou","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e34094_bib30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jnci\/djh064","article-title":"Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas","volume":"96","author":"Knobbe","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.heliyon.2024.e34094_bib31","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/ijc.24424","article-title":"Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma","volume":"125","author":"Simon","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e34094_bib32","first-page":"1515","article-title":"Carboxyl-terminal modulator protein induces apoptosis by regulating mitochondrial function in lung cancer cells","volume":"40","author":"Hwang","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.heliyon.2024.e34094_bib33","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1158\/0008-5472.CAN-13-0518","article-title":"Carboxyl-terminal modulator protein positively regulates Akt phosphorylation and acts as an oncogenic driver in breast cancer","volume":"73","author":"Liu","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e34094_bib34","article-title":"Carboxyl-terminal modulator protein positively acts as an oncogenic driver in head and neck squamous cell carcinoma via regulating Akt phosphorylation","volume":"6","author":"Chang","year":"2016","journal-title":"Sci. Rep."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024101259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024101259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:49:55Z","timestamp":1778885395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024101259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":34,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405844024101259"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34094","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PRAME promotes proliferation of multiple myeloma cells through CTMP\/Akt\/p21\/CCND3 axis by ubiquitinating CTMP and p21","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e34094"}}